Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Open-Label, Study of a Novel Targeted Radiotherapy in Children, Adolescents and Young Adults With Inoperable Relapsed or Refractory High-Grade Glioma

NCT05610891 is registered in ClinicalTrials.gov with Cellectar Biosciences, Inc. as lead sponsor.

NCT NCT05610891
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05610891 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Open-Label, Study of a Novel Targeted Radiotherapy in Children, Adolescents and Young Adults With Inoperable Relapsed or Refractory High-Grade Glioma
Lead sponsor
Cellectar Biosciences, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
October 1, 2023
Completion date
December 31, 2027
Enrollment
50 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

high-grade glioma